CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS CALT 深 滬
交易中 09-16 16:01:16 美东时间
40.75
+0.750
+1.88%
華盛通- 最 高40.75
- 今 開40.37
- 成交量 2923股
- 最 低 40.09
- 昨 收 40.00
- 總市值 10.94亿
- 52周最高 42.10
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 15.25
- 委 比 -20.04%
- 總股本 2683.60万
- 歷史最高 42.10
- 量 比 0.81
- 振 幅 1.65%
- 歷史最低 10.82
- 每 手 1
- 風險率 9.02%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Calliditas Therapeutics to be delisted from Nasdaq Stockholm
Calliditas Therapeutics AB (NASDAQ:CALT) said on Monday that Nasdaq Stockholm has decided the company will be delisted from Nasdaq Stockholm. The last day of trading in the share will be on Thursday, ...
09-16 22:45
Calliditas Therapeutics Sets Delisting Process
Calliditas Therapeutics (CALT) has released an update. Calliditas Therapeutics,...
09-04 04:51
Asahi Kasei Expands Global Pharma Presence with Calliditas Acquisition
Asahi Kasei (JP:3407) has released an update. Asahi Kasei Corporation successfu...
09-03 09:27
Calliditas Therapeutics Sees Strong Sales Growth
Calliditas Therapeutics (CALT) has released an update. Calliditas Therapeutics ...
08-14 04:38
Calliditas Therapeutics Q2 2024 GAAP EPS $(0.17) Misses $(0.13) Estimate, Sales $52.351M Beat $42.952M Estimate
Calliditas Therapeutics (NASDAQ:CALT) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.13) by 26.92 percent. This is a 49.23 percent increase over losses of $(0.33) per
08-13 13:40
Novartis gets FDA approval for Fabhalta in IgAN patients
Novartis (NYSE:NVS) has received FDA accelerated approval for its drug Fabhalta to be used in the reduction of proteinuria in adults with primary immunoglobulin A nephropathy, or IgAN, at risk of rapi...
08-08 04:57
Number of Shares and Votes in Calliditas Therapeutics
STOCKHOLM, July 31, 2024 /PRNewswire/ -- During July, the number of shares and ...
07-31 20:23
Calliditas’ Setanaxib Shows Promise in PBC Trial
Calliditas Therapeutics (CALT) has released an update. Calliditas Therapeutics ...
07-27 04:27
Calliditas's Kinpegyo gets EU approval, setanaxib study meets endpoint
Calliditas (NASDAQ:CALT) said its partner STADA has received full EU marketing authorization for the drug Kinpeygo for the treatment of adults with primary immunoglobulin A nephropathy, or IgAN. Kinpe...
07-27 03:52
Calliditas Therapeutics Reports TRANSFORM Phase 2b Topline Data In Primary Biliary Cholangitis
alliditas Therapeutics AB (NASDAQ:CALT) (STOCKHOLM: CALTX) ("Calliditas") today announced that the Phase 2b TRANSFORM trial met its primary endpoint, showing statistically significant
07-26 14:53
